Hypofractionated stereotactic radiotherapy for the treatment of brain metastases

Cancer
Alexander K KwonYunping Zhu

Abstract

This retrospective review evaluated the efficacy and toxicity profiles of various dose fractionations using hypofractionated stereotactic radiotherapy (HSRT) in the treatment of brain metastases. Between 2004 and 2007, 36 patients with 66 brain metastases were treated with HSRT. Nine of these subjects were excluded because of the absence of post-treatment magnetic resonance imaging scans, resulting in 27 patients with a total of 52 lesions. Of these 52 lesions, 45 lesions were treated with whole-brain radiotherapy plus a HSRT boost and 7 lesions were treated with HSRT as the primary treatment. The median prescribed dose was 25 grays (Gy) (range, 20 Gy-36 Gy) with a median of 5 fractions (range, 4 fractions-6 fractions) to a median 85% isodose line (range, 50%-100%). The median follow-up interval was 6.6 months (range, 0.9 months-26.8 months). The median overall survival time was 10.8 months, and 66.7% of patients died of disease progression. After HSRT treatment of 52 brain lesions, 13 lesions demonstrated complete responses, 12 lesions demonstrated partial responses, 22 lesions demonstrated stable disease, and 5 lesions demonstrated progressive disease. Actuarial local tumor control rates at 6 months and 1 year were 93.9% and ...Continue Reading

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Jan 15, 1993·International Journal of Radiation Oncology, Biology, Physics·E J Hall, D J Brenner
Jan 15, 1997·International Journal of Radiation Oncology, Biology, Physics·S F ShepherdM Brada
Mar 1, 1997·International Journal of Radiation Oncology, Biology, Physics·L GasparR Byhardt
Sep 16, 1999·International Journal of Radiation Oncology, Biology, Physics·D KondziolkaJ C Flickinger
Jun 6, 2000·International Journal of Radiation Oncology, Biology, Physics·M A ManningW C Broaddus
Sep 6, 2003·International Journal of Radiation Oncology, Biology, Physics·John M VarlottoL Dale Lunsford
Apr 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Peter LindvallA Tommy Bergenheim
Apr 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Reena KamathJohn M Buatti
Oct 11, 2005·Journal of Neuro-oncology·R SoffiettiR Rudà
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rafael ManonUNKNOWN Eastern Cooperative Oncology Group
Sep 5, 2006·Critical Reviews in Oncology/hematology·Gregory M RichardsMinesh P Mehta
Sep 19, 2006·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Antje Ernst-SteckenGerhard Grabenbauer

❮ Previous
Next ❯

Citations

May 1, 2012·Journal of Neuro-oncology·Shoji YomoClaire Nicholson
Dec 18, 2013·Clinical Oncology : a Journal of the Royal College of Radiologists·T MuraiY Shibamoto
Jan 21, 2014·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·L FeuvretJ-J Mazeron
Apr 25, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Bruno De PotterPiet Ost
Jan 15, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Marcello MarchettiLaura Fariselli
Aug 31, 2010·International Journal of Radiation Oncology, Biology, Physics·Yeon-Joo KimSeung Hoon Lee
Dec 17, 2009·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·M SchliengerE Touboul
Jun 10, 2014·Health Care for Women International·Areej OthmanManal Shahrouri
Oct 25, 2012·International Journal of Radiation Oncology, Biology, Physics·Tomohiko MatsuyamaNatsuo Oya
Apr 9, 2013·American Journal of Clinical Oncology·Rodney E WegnerDwight E Heron
May 14, 2016·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Takeaki IshiharaRyohei Sasaki
Jul 7, 2016·Neuro-oncology·Nils D ArvoldPatrick Y Wen
Apr 24, 2014·American Journal of Clinical Oncology·Kamran A AhmedNikhil G Rao
Nov 6, 2015·Journal of Korean Neurosurgical Society·Won Joo JeongYoung Hyun Cho
Apr 6, 2017·Neuro-oncology·John P KirkpatrickPaul D Brown
Jan 1, 2010·Cancers·Alexander Chi, Ritsuko Komaki
Nov 7, 2018·Journal of Korean Neurosurgical Society·Kyoung Jun YoonYoung Hyun Cho
Feb 4, 2014·Journal of Neuro-oncology·Giuseppe MinnitiLucio Trodella
Feb 21, 2013·Chemical Communications : Chem Comm·Zane B StarkewolfTing Guo
Aug 17, 2018·Medicines·Mark O'BeirnPaul Sanghera

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.